2. UroToday Home
  3. Video Lectures

APCCC 2024 Conference Presentations Videos

APCCC 2024 Highlights Patient Voice in Cancer Treatment "Presentation" - Silke Gillessen, Aurelius Omlin & David Matheson
Challenges in Defining High-Risk Localized Prostate Cancer for Optimal Treatment "Presentation" - Martin Gleave
What is the Role of DRE in the Modern Imaging Era? "Presentation" - Declan Murphy
Regional Lymph Node Staging for High-Risk and Locally Advanced Prostate Cancer – What Should be the Standard? “Presentation” - Jochen Walz
Genomic Classifiers and Artificial Intelligence (AI) as Predictors for Treatment Benefit "Presentation" - Daniel Spratt
Impact of Imaging and Biopsy Techniques on Treatment Decisions "Discussion"
Radiation Therapy Schedules and Fields for Highrisk and Locally Advanced Prostate Cancer "Presentation" - Neha Vapiwala
Surgery as Radical Local Treatment (As Part of a Multimodality Approach) "Presentation" - Alberto Briganti
Radiation Therapy as Radical Local Treatment (As Part of a Multimodality Approach) "Presentation" - Piet Ost
How to Select Patients for Adjuvant Therapy After Radical Prostatectomy and How to Treat Them? "Presentation" - Jason Efstathiou
Surgery vs Radiation vs Multimodal Prostate Cancer Treatment "Discussion"
How to Manage Patients with PSA Persistence Following Radical Prostatectomy? "Presentation" Derya Tilki
How to Select Patients with Biochemical Relapse in Whom Salvage Radiation Therapy Can be Postponed? "Presentation" - Barbara Alicja Jereczek-Fossa
Which Patients with High-Risk First BCR After Radical Prostatectomy are Candidates for Systemic Therapy Alone Without Local Salvage RT? "Presentation" - Bertrand Tombal
In Patients Who Receive Salvage Radiation Therapy For BCR, Who Needs Additional Systemic Therapy, What and For How Long?" Presentation" - Daniel Spratt
Timing of Salvage Radiotherapy in Recurrent Prostate Cancer Management "Discussion"
In Patients with BCR and Positive Lesion(s) in the Pelvis – Stereotactic or Whole Pelvis RT? "Presentation" - Paul Nguyen
Managing Gynecomastia in ARPI Prostate Cancer Treatment "Presentation" - Neal Shore
Second BCR (Without Correlate on NGI) After Salvage Radiation And/or After Metastases Directed Therapy: How to Manage These Patients "Presentation" - Ray McDermott
Treatment for Biochemical Recurrence/PSA Persistence "Discussion"
Introduction to mHSPC: Key Prognostic and Predictive Factors "Presentation" - Matthew Smith
Low-Volume mHSPC: When to Intensify Treatment "Presentation" - Robert Jones
In Which Patients with Synchronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Oliver Sartor
Which Patients with mHSPC Should Get Triplet Systemic Therapy: ADT plus Docetaxel plus ARPI? "Presentation" - Nicholas James
Should the Primary be Treated in Synchronous High-Volume mHSPC? "Presentation" - Sandy Srinivas
In Which Patients with Metachronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Thomas Zilli
Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice? "Presentation" - Michael Morris
Optimal Treatment Sequencing in Metastatic Prostate Cancer "Discussion"
Update on the IRONMAN Project "Presentation" - Alicia Morgans
Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break? "Presentation" - Bertrand Tombal
Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better? "Presentation" - Mary-Ellen Taplin
How to Manage Patients with Low-Volume on Conventional and High-Volume on NGI "Presentation" - Dana Rathkopf
Management of Patients with mHSPC and Early Progression on Combination Therapy "Presentation" - Christopher Sweeney
Management of Frail Patients with mHSPC "Presentation" - Maria De Santis
Future Changes in the Setting of mHSPC "Presentation" - Gerhardt Attard
Patient Preferences in Prostate Cancer De-Escalation Strategies "Discussion"
Cardiovascular Complications in Advanced Prostate Cancer – How to Prevent Them and How to Monitor Patients? "Presentation" - Thomas Suter
How to Select ADT and ARPI Based on CV Risk Profile "Presentation" - Charles Ryan
Importance of Bone Protection in Prostate Cancer Treatment "Presentation" - Noel Clarke
Gynecomastia – How to Assess and Treat? "Presentation" - Lisa Horvath
Hot Flushes – How Can We Help Our Patients? "Presentation" - Anthony Joshua
Testosterone Recovery After Stopping ADT – Who Is at Risk for Long-Term Non-Recovery? "Presentation" - Pierre Blanchard
Balancing Risks and Benefits of ADT in Prostate Cancer Treatment "Discussion"
Tailoring PARP Inhibitor Therapy for mCRPC Based on Genetic Alterations "Discussion"
When to Do Tumour Genomic Profiling in Advanced Prostate Cancer and What? "Presentation" - Niven Mehra
Ideal Sequence After ADT Alone or ADT plus ARPI for mHSPC "Presentation" - Ian Davis
Ideal Sequence After ADT plus ARPI plus Docetaxel for mHSPC "Presentation" - Karim Fizazi
Best Use of PARP Inhibitors in mCRPC "Presentation" - Joaquin Mateo
PARP Inhibition Dissected – in Which DNA Repair Gene Alterations Works Which PARP Inhibitor? "Presentation" - Johann De Bono
How to Manage Side Effects of PARPi? "Presentation" - Elena Castro
Managing PSA Recurrence After Prostate Cancer Surgery Treatment "Discussion"
PARP Inhibitors in Prostate Cancer Challenges and Opportunities in Clinical Practice "Discussion"
Lancet Commission on Prostate Cancer– the Forthcoming Surge in Prostate Cancer Raises Very Different Issues to the Ones We Face Today "Presentation" - Nicholas James
How Do We Maximize Use of Radiotherapy for Prostate Cancer in Africa "Presentation" - Omolara Aminat Fatiregun
How Do We Modify the Diagnostic Pathway to Deal with Rising Rates of Prostate Cancer in Africa? "Presentation" - Onyeanunam Ngozi Ekeke
Dealing with Inequalities: What Can We Learn from the Indian Healthcare System? "Presentation" - Vedang Murthy
Dealing with Inequality - the Promise and Pitfalls for Social Media and AI for Prostate Cancer in Disadvantaged Populations "Presentation" - Stacy Loeb
Dealing with Inequality – What Can We Learn from the Brazilian Unified Healthcare System (SUS) – Opportunities for Big Data Mining and System Remodelling "Presentation" - Fernando Maluf
How to Deal with the Projected Rise of Prostate Cancer Cases in the Chinese Healthcare System "Presentation" - Dingwei Ye
Global Cancer Care Challenges & Solutions in Developing Nations "Discussion"
How To Interpret and Confirm Lesions Positive on PSMA PET but With No Correlation on CT? APCCC 2022 Presentation - Stefano Fanti
Does “Oligoprogressive” Prostate Cancer Exist as a Distinct Clinically Meaningful Entity and if Yes, How To Treat It? APCCC 2022 Presentation - Robert Jones
What is the Evidence of MDT in Synchronous vs Metachronous mHSPC? APCCC 2022 Presentation - Daniel Spratt
Are There Predictors for Successful Treatment of Oligometastatic Prostate Cancer? APCCC 2022 Presentation - Piet Ost
Treatment of Vulnerable/Frail Patients with mHSPC APCCC 2022 Presentation - Alicia Morgans
What Is the Evidence of Systemic Therapies (Alone or in Combination With MDT) in Oligometastatic mHSPC? APCCC 2022 Presentation - Mary Ellen Taplin
Impact of Histology Variants (Ductal/Intraductal/Cribriform) on Treatment Recommendation Presentation - Declan Murphy
Update on Immune Checkpoint Inhibitors APCCC 2022 Presentation - Emmanuel Antonarakis
Optimal Treatment for mHSPC from a Health Economics Standpoint APCCC 2022 Presentation - Caroline Clarke
Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment APCCC 2022 Presentation - Eric Small
Debate: PARP Inhibitors for All mCRPC Patients APCCC 2022 Presentation - Noel Clarke
Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of Muscle Strength? APCCC 2022 Presentation - Heather Cheng
Risk-Adapted Treatment Monitoring in mCRPC APCCC 2022 Presentation - Anwar Padhani
Is There Still a Role for Radium-223? APCCC 2022 Presentation - Neal Shore
Can Biology Help Inform Treatment Decisions In the Management of mHSPC? APCCC 2022 Presentation - Gert Attard
When Low-Volume on Conventional Imaging Goes into High-Volume on Next-Generation Imaging in mHSPC - Treat like High-Volume APCCC 2022 Presentation - Ian Davis
Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of the Bones? APCCC 2022 Presentation - Oliver Sartor
How To Read a Genomic Testing Report APCCC 2022 Presentation - Kim Chi
Lutetium-PSMA Therapy APCCC 2022 Presentation - Matthew Smith
Optimal Treatment Sequencing in mCRPC APCCC 2022 Presentation - Maha Hussain
Treating Metastatic Castration-Resistant Prostate Cancer Session Discussion APCCC 2022 Presentation - Silke Gillessen
Treatment De-escalation Strategies in mHSPC APCCC 2022 Presentation - Bertrand Tombal
Treatment Intensification Strategies in mHSPC: Triplets and More APCCC 2022 Presentation - Christopher Sweeney
mHSPC: Low-Volume on Conventional vs High-Volume on Next-Gen Imaging – Treat as Low-Volume – Karim Fizazi
When Low-Volume on Conventional Imaging Goes into High-Volume on Next-Generation Imaging in mHSPC - How Frequent Is This Situation? APCCC 2022 Presentation - Michael Hofman
The Uptake of New Treatment Options for mHSPC in Real Life -- Education, Access, Use, and Diversity APCCC 2022 Presentation - Andrew Armstrong
Debate: PARP Inhibitors Only in Selected mCRPC Patients APCCC 2022 Presentation - Johann de Bono
Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of Brain and Mood? Presentation APCCC 2022 - Charles Ryan
Management of pN1 Prostate Cancer (Including Systemic Therapy) APCCC 2022 Presentation - Derya Tilki
Disadvantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Alberto Briganti
Advantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Michael Morris
M0 CPRC: Overview of Treatment Options APCCC 2022 Presentation - Eleni Efstathiou
Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of the Heart? APCCC 2022 Presentation - Fred Saad
Biochemical Recurrence After Definitive Radiotherapy of the Prostate – What Are the Local Treatment Options? APCCC 2022 Presentation - Jochen Walz
Who Needs Systemic Treatment With Salvage Radiotherapy? APCCC 2022 Presentation - Brandon Mahal
Imaging Directed Treatment for Biochemical Recurrence APCCC 2022 Presentation - Nicholas James
Who Needs Early Salvage RT and Who Needs Adjuvant RT in 2022? APCCC 2022 Presentation - Kosj Yamoah
Management of Clinical N1 Prostate Cancer (Including Systemic Therapy) APCCC 2022 Presentation - Darren Poon
Are We Ready to Change Management Based on Next-Generation Imaging? No APCCC 2022 Presentation - Nicolas Mottet
Are We Ready to Change Management Based on Next-Generation Imaging? YES: APCCC 2022 Presentation - Jason Efstathiou
PSA Directed Treatment for BCR APCCC 2022 Presentation - Neha Vapiwala